Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
Abstract Background Biologic therapies are often prescribed for patients with rheumatoid arthritis (RA) who have inadequate responses to or are intolerant of methotrexate (MTX) and patients with poor prognostic indicators. This post hoc analysis evaluated effectiveness and safety of intravenous goli...
Main Authors: | Aaron Broadwell, Joy Schechtman, Douglas Conaway, Alan Kivitz, Natalie J. Shiff, Shawn Black, Stephen Xu, Wayne Langholff, Sergio Schwartzman, Jeffrey R. Curtis |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | BMC Rheumatology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41927-023-00329-8 |
Similar Items
-
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
by: Clifton O. Bingham, et al.
Published: (2023-02-01) -
Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study
by: Atul Deodhar, et al.
Published: (2023-06-01) -
Serum IL-13 Predicts Response to Golimumab in Bio-Naïve Ulcerative Colitis
by: Naohiko Kinoshita, et al.
Published: (2022-08-01) -
Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial
by: Philip Mease, et al.
Published: (2020-03-01) -
Combination intravenous immunoglobulin, oral prednisone, and methotrexate for managing scleromyxedema: case report and literature discussion
by: Gaia Fasano, et al.
Published: (2023-08-01)